Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.50 |
| ▸ | TEK | Q02763 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2823001 | 0.88 | HDAC1 (0.63) | NOTUMHDAC1KDM1ATGM2EPHB4 | |
| SCHEMBL2819423 | 0.85 | NOTUM (0.68) | NOTUMHDAC1HSP90AB1HSP90AA1CYP19A1 | |
| SCHEMBL16206205 | 0.83 | NOTUM (0.73) | NOTUMHDAC1KDM1AHSP90AB1CYP19A1 | |
| SCHEMBL2821939 | 0.83 | NOTUM (0.57) | NOTUMHDAC1KDM1AEPHB4TEK | |
| SCHEMBL28263507 | 0.81 | EPHB4 (0.52) | NOTUMHDAC1KDM1ATGM2EPHB4 | |
| SCHEMBL2822823 | 0.81 | NOTUM (0.62) | NOTUMHDAC1KDM1AS1PR1HSP90AB1 | |
| SCHEMBL2819739 | 0.81 | NOTUM (0.62) | NOTUMHDAC1S1PR1HSP90AB1CYP19A1 | |
| SCHEMBL28863788 | 0.81 | NOTUM (0.71) | NOTUMHSP90AB1CYP19A1MAPT | |
| SCHEMBL6980467 | 0.81 | NOTUM (1.00) | NOTUMHDAC1HSP90AB1CYP19A1MAPT | |
| SCHEMBL12885309 | 0.80 | NOTUM (0.73) | NOTUMHDAC1HSP90AB1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083601-B1 | PIPERIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-09-09 | — | — | EP | disclosed |
| CN-105849096-B | Piperidine derivatives having multimodal activity against pain | 埃斯蒂文制药股份有限公司 | 2019-11-29 | — | — | CN | disclosed |
| US-9981942-B2 | Piperidine derivatives having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-05-29 | — | — | US | disclosed |
| US-9981942-B2 | Piperidine derivatives having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-05-29 | — | — | US | disclosed |
| US-20170001978-A1 | PIPERIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-01-05 | — | — | US | disclosed |
| US-20170001978-A1 | PIPERIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-01-05 | — | — | US | disclosed |
| EP-3083601-A1 | PIPERIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-10-26 | — | — | EP | disclosed |
| CN-105849096-A | Piperidine derivatives having multimodal activity against pain | 埃斯蒂文博士实验室股份有限公司 | 2016-08-10 | — | — | CN | disclosed |
| WO-2015091939-A1 | PIPERIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-06-25 | — | — | WO | disclosed |
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | disclosed |
| WO-2010071813-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α | ARYX THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001978-A1 | PIPERIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, OPRM1, OPRK1 | NOTUM 2813/4885HDAC1 853/4885KDM1A 4423/4885 |
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | PPARA, PPARD, PPARG | NOTUM 815/4885HDAC1 1167/4885KDM1A 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.